SIGMAR1 and melanoma: Because upregulation of counteracting signaling cascades as a direct response to MEK inhibition limits the efficacy of MEK inhibitors in melanoma patients 23, our results pinpoint the synergistic effect of AAG8 antagonism and MEK inhibition and suggest AAG8 plus MEK inhibitory combination therapy as a potential therapeutic strategy for melanoma.